Medigen Vaccine Biologics Corp. Statistics
Medigen Vaccine Biologics Corp. (6547) Stock Statistics & Valuation Metrics
Total Valuation
Medigen Vaccine Biologics Corp. has a market cap or net worth of TWD 15.43B. The enterprise value is TWD 14.01B.
- Market Cap
- TWD 15.43B
- Enterprise Value
- TWD 14.01B
Share Statistics
Medigen Vaccine Biologics Corp. has 328,943,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 328,943,630
- Owned by Insiders
- ―
- Owned by Institutions
- 2.65%
Financial Efficiency
Medigen Vaccine Biologics Corp.’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -7.06%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -7.06%
- Return on Capital Employed (ROCE)
- -0.07
- Revenue Per Employee
- 500.14K
- Profits Per Employee
- -229.78K
- Employee Count
- 1,226
- Asset Turnover
- 0.16
- Inventory Turnover
- 0.63
Valuation Ratios
The current PE Ratio of Medigen Vaccine Biologics Corp. is -435.41. Medigen Vaccine Biologics Corp.’s PEG ratio is 16.34.
- PE Ratio
- -435.41
- PS Ratio
- 18.96
- PB Ratio
- 4.64
- Price to FCF
- -74.88
- Price to Operating Cash Flow
- -298.02
- PEG Ratio
- 16.34
Income Statement
In the last 12 months, Medigen Vaccine Biologics Corp. had revenue of 613.17M and earned -281.71M in profits. Earnings per share was -0.86.
- Revenue
- 613.17M
- Gross Profit
- 364.67M
- Operating Income
- -265.69M
- Pretax Income
- -281.71M
- Net Income
- -281.71M
- EBITDA
- -123.90M
- Earnings Per Share (EPS)
- -0.86
Cash Flow
In the last 12 months, operating cash flow was -55.34M and capital expenditures -162.21M, giving a free cash flow of -217.55M billion.
- Operating Cash Flow
- -55.34M
- Free Cash Flow
- -217.55M
- Free Cash Flow per Share
- -0.65
Dividends & Yields
Medigen Vaccine Biologics Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.36%
- Earnings Yield
- -0.22%
Stock Price Statistics
- Beta
- 0.25
- 52-Week Price Change
- 38.96%
- 50-Day Moving Average
- 57.01
- 200-Day Moving Average
- 49.32
- Relative Strength Index (RSI)
- 29.58
- Average Volume (3m)
- 4.17M
Important Dates
Medigen Vaccine Biologics Corp. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Medigen Vaccine Biologics Corp. as a current ratio of 12.77, with Debt / Equity ratio of 8.15%
- Current Ratio
- 12.77
- Quick Ratio
- 10.64
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.49
- Interest Coverage Ratio
- -30.19
Taxes
In the past 12 months, Medigen Vaccine Biologics Corp. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Medigen Vaccine Biologics Corp. EV to EBITDA ratio is 78.76, with an EV/FCF ratio of -77.47.
- EV to Sales
- 19.62
- EV to EBITDA
- 78.76
- EV to Free Cash Flow
- -77.47
- EV to Operating Cash Flow
- -304.52
Balance Sheet
Medigen Vaccine Biologics Corp. has TWD 2.04B in cash and marketable securities with TWD 1.10B in debt, giving a net cash position of TWD 936.80M billion.
- Cash & Marketable Securities
- TWD 2.04B
- Total Debt
- TWD 1.10B
- Net Cash
- TWD 936.80M
- Net Cash Per Share
- TWD 2.85
- Tangible Book Value Per Share
- TWD 10.48
Margins
Gross margin is 60.59%, with operating margin of 10.20%, and net profit margin of -4.07%.
- Gross Margin
- 60.59%
- Operating Margin
- 10.20%
- Pretax Margin
- -4.07%
- Net Profit Margin
- -4.07%
- EBITDA Margin
- 24.91%
- EBIT Margin
- 10.20%
Analyst Forecast
The average price target for Medigen Vaccine Biologics Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 44.37%
- EPS Growth Forecast
- 78.11%
